thalidomide has been researched along with Tuberculosis in 19 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Tuberculosis: Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide, which inhibits monocyte tumor necrosis factor (TNF)-alpha production and costimulates T cells, was tested for immune modulation in patients with human immunodeficiency virus (HIV) infection and tuberculosis (TB) in a placebo-controlled study." | 9.09 | Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. ( Bekker, LG; Haslett, P; Kaplan, G; Maartens, G; Steyn, L, 2000) |
| "To evaluate the efficacy of thalidomide for treating troublesome cases of pediatric Crohn's disease (CD) with tuberculosis infection." | 7.85 | Efficacy of thalidomide therapy in pediatric Crohn's disease with evidence of tuberculosis. ( Hong, Y; Huang, Y; Leung, YK; Wang, L; Wu, J, 2017) |
| "Thalidomide, which inhibits monocyte tumor necrosis factor (TNF)-alpha production and costimulates T cells, was tested for immune modulation in patients with human immunodeficiency virus (HIV) infection and tuberculosis (TB) in a placebo-controlled study." | 5.09 | Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis. ( Bekker, LG; Haslett, P; Kaplan, G; Maartens, G; Steyn, L, 2000) |
| "To evaluate the efficacy of thalidomide for treating troublesome cases of pediatric Crohn's disease (CD) with tuberculosis infection." | 3.85 | Efficacy of thalidomide therapy in pediatric Crohn's disease with evidence of tuberculosis. ( Hong, Y; Huang, Y; Leung, YK; Wang, L; Wu, J, 2017) |
| " This study evaluated the effect of thalidomide on lipopolysaccharide (LPS)-induced TNF-alpha production by human alveolar macrophages obtained from patients with tuberculosis and a group of other diseases associated with macrophage activation." | 3.69 | Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages. ( Dilworth, P; Kotecha, S; Marshall, B; Shaw, RJ; Tavares, JL; Wangoo, A, 1997) |
| "Thalidomide is being tested as an anti-HIV drug, a weight loss treatment, an immune system regulator, a tuberculosis treatment supplement, and a treatment for microsporidiosis." | 3.69 | Treatment for weight loss, tuberculosis and AIDS? ( , 1995) |
| " Others report on the use of thalidomide or IL-10 for curtailing or suppressing tumor necrosis factor alpha in coincident HIV and tuberculosis patients." | 3.69 | Or is it the host, sir? ( Mascolini, M, 1996) |
| "Management of relapsing or refractory immune reconstitution inflammatory syndromes (IRISs) despite corticosteroid therapy is yet to be defined." | 1.38 | Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS. ( Brunel, AS; Le Moing, V; Lortholary, O; Makinson, A; Montes, B; Reynes, J; Rubbo, PA; Tuaillon, E, 2012) |
| "Treatment with thalidomide neither consistently altered mycobacterial burden in the spleens or livers of infected mice nor affected serum TNF-alpha levels." | 1.30 | Inhibition of tumor necrosis factor alpha alters resistance to Mycobacterium avium complex infection in mice. ( Bala, S; Dempsey, WL; Hastings, KL; Inglis, S; Kazempour, K, 1998) |
| "Thalidomide trials have been slow to recruit, therefore buyers clubs are working to make the drug available through their services." | 1.29 | Thalidomide and HIV: several possible uses. ( Smith, D, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 6 (31.58) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Fernández, GI | 1 |
| Ribera, JM | 1 |
| Sabater, LA | 1 |
| Vieira, M | 1 |
| Vautier, M | 1 |
| Charlotte, F | 1 |
| Saadoun, D | 1 |
| Wang, L | 1 |
| Hong, Y | 1 |
| Wu, J | 1 |
| Leung, YK | 1 |
| Huang, Y | 1 |
| Kawai, T | 1 |
| Watanabe, N | 1 |
| Yokoyama, M | 1 |
| Arai, K | 1 |
| Oana, S | 1 |
| Harayama, S | 1 |
| Yasui, K | 1 |
| Oh-Ishi, T | 1 |
| Onodera, M | 1 |
| Fourcade, C | 1 |
| Mauboussin, JM | 1 |
| Lechiche, C | 1 |
| Lavigne, JP | 1 |
| Sotto, A | 1 |
| Koo, MS | 2 |
| Manca, C | 1 |
| Yang, G | 2 |
| O'Brien, P | 2 |
| Sung, N | 1 |
| Tsenova, L | 2 |
| Subbian, S | 2 |
| Fallows, D | 2 |
| Muller, G | 2 |
| Ehrt, S | 1 |
| Kaplan, G | 4 |
| Peixoto, B | 1 |
| Dartois, V | 1 |
| Brunel, AS | 1 |
| Reynes, J | 1 |
| Tuaillon, E | 1 |
| Rubbo, PA | 1 |
| Lortholary, O | 1 |
| Montes, B | 1 |
| Le Moing, V | 1 |
| Makinson, A | 1 |
| SCHIEFER, I | 1 |
| Tavares, JL | 1 |
| Wangoo, A | 1 |
| Dilworth, P | 1 |
| Marshall, B | 1 |
| Kotecha, S | 1 |
| Shaw, RJ | 1 |
| Bala, S | 1 |
| Hastings, KL | 1 |
| Kazempour, K | 1 |
| Inglis, S | 1 |
| Dempsey, WL | 1 |
| Holland, SM | 1 |
| Bekker, LG | 1 |
| Haslett, P | 1 |
| Maartens, G | 1 |
| Steyn, L | 1 |
| Gori, A | 1 |
| Rossi, MC | 1 |
| Marchetti, G | 1 |
| Trabattoni, D | 1 |
| Molteni, C | 1 |
| Cogliati, M | 1 |
| Bandera, A | 1 |
| Clerici, M | 1 |
| Franzetti, F | 1 |
| Smith, D | 1 |
| Mascolini, M | 1 |
| Fu, LM | 1 |
| Fu-Liu, CS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00004276] | Phase 2 | 50 participants | Interventional | 1990-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thalidomide and Tuberculosis
| Article | Year |
|---|---|
Cytokine therapy of mycobacterial infections.
Topics: Adjuvants, Immunologic; Anti-Infective Agents; Cytokines; Drug Resistance, Microbial; Drug Therapy, | 2000 |
Thalidomide and tuberculosis.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Count; Child; Clinical Trials | 2002 |
2 trials available for thalidomide and Tuberculosis
| Article | Year |
|---|---|
Cytokine regulation of disease progression in leprosy and tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Cytokines; Erythema Nodosum; HIV-1; Humans; Immunity, Cellula | 1994 |
Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis.
Topics: Acquired Immunodeficiency Syndrome; Adjuvants, Immunologic; Adult; Body Mass Index; CD40 Ligand; Cyt | 2000 |
15 other studies available for thalidomide and Tuberculosis
| Article | Year |
|---|---|
Tuberculosis during lenalidomide maintenance in a patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Maintenance Chemotherapy; Mult | 2021 |
Mycobacterium bovis infection under apremilast in Behçet's syndrome.
Topics: Antitubercular Agents; Behcet Syndrome; Female; Humans; Middle Aged; Mycobacterium bovis; Phosphodie | 2021 |
Efficacy of thalidomide therapy in pediatric Crohn's disease with evidence of tuberculosis.
Topics: Adolescent; Antitubercular Agents; Blood Sedimentation; Body Weight; C-Reactive Protein; Child; Chil | 2017 |
Thalidomide attenuates excessive inflammation without interrupting lipopolysaccharide-driven inflammatory cytokine production in chronic granulomatous disease.
Topics: Adenosine Triphosphate; Caspase 1; Cells, Cultured; Child, Preschool; Cytokines; Granulomatous Disea | 2013 |
Thalidomide in the treatment of immune reconstitution inflammatory syndrome in HIV patients with neurological tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active | 2014 |
Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice.
Topics: Animals; Antibiotics, Antitubercular; Bacterial Load; Cyclic Nucleotide Phosphodiesterases, Type 4; | 2011 |
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs.
Topics: Animals; Antitubercular Agents; Bacterial Load; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Ty | 2011 |
Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antiretroviral The | 2012 |
[On clinical experiences with contergan in tuberculous children].
Topics: Anesthesia; Child; Hypnotics and Sedatives; Infant; Thalidomide; Tuberculosis | 1960 |
Thalidomide reduces tumour necrosis factor-alpha production by human alveolar macrophages.
Topics: Adult; Aged; Aged, 80 and over; Cells, Cultured; Female; Humans; Immunohistochemistry; Immunosuppres | 1997 |
Inhibition of tumor necrosis factor alpha alters resistance to Mycobacterium avium complex infection in mice.
Topics: Animals; Dexamethasone; Female; Mice; Mice, Inbred C57BL; Mycobacterium avium; Pentoxifylline; Thali | 1998 |
Clinical and immunological benefit of adjuvant therapy with thalidomide in the treatment of tuberculosis disease.
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Cytokines; Female; HIV Seronegativity; HIV Serop | 2000 |
Thalidomide and HIV: several possible uses.
Topics: AIDS-Related Opportunistic Infections; Cachexia; Clinical Trials as Topic; HIV Infections; Humans; N | 1995 |
Treatment for weight loss, tuberculosis and AIDS?
Topics: Acquired Immunodeficiency Syndrome; Cachexia; Clinical Trials as Topic; Humans; Stomatitis, Aphthous | 1995 |
Or is it the host, sir?
Topics: Adjuvants, Immunologic; AIDS-Related Opportunistic Infections; Anti-Infective Agents; CD8-Positive T | 1996 |